Hematology Tablet Franchise in Ahmedabad

Eltrombopag Tablet Supplier in Mumbai

Platelet Booster Tablet Distributor in Delhi

Thrombopoietin Receptor Agonist Manufacturer in Bangalore

Thrombocytopenia Treatment Tablet Stockist in Hyderabad
Hematology Medicine Exporter in Chandigarh

Home/Products /eltrombopag-50mg-tablet

Eltrohype 50 Tablet

Composition : Eltrombopag (50mg) Tablet

Dosage Form : Tablet

Packaging Type : Alu Alu

Packaging : 2x7

Price : ₹0/-

Eltrombopag 50 mg Tablet is a thrombopoietin receptor agonist indicated for the management of chronic immune thrombocytopenia (ITP) and thrombocytopenia associated with chronic hepatitis C. It supports an increase in platelet count and helps reduce the risk of bleeding.

The medication works by stimulating thrombopoietin receptors in the bone marrow, promoting platelet production without suppressing immune function. This targeted action makes it suitable for patients requiring controlled platelet elevation.

Clinically, Eltrombopag 50 mg Tablet is prescribed for patients with persistently low platelet counts who do not respond adequately to first-line therapies, supporting stable hematological outcomes under specialist supervision.

With its importance in long-term hematology treatment and consistent prescription demand, this therapy helps strengthen specialty medicine portfolios and supports sustained growth by addressing critical platelet management needs in clinical practice.

Read More

About the Product

Eltrombopag 50 mg Tablet is a thrombopoietin receptor agonist indicated for the management of chronic immune thrombocytopenia (ITP) and thrombocytopenia associated with chronic hepatitis C. It supports an increase in platelet count and helps reduce the risk of bleeding.

The medication works by stimulating thrombopoietin receptors in the bone marrow, promoting platelet production without suppressing immune function. This targeted action makes it suitable for patients requiring controlled platelet elevation.

Clinically, Eltrombopag 50 mg Tablet is prescribed for patients with persistently low platelet counts who do not respond adequately to first-line therapies, supporting stable hematological outcomes under specialist supervision.

With its importance in long-term hematology treatment and consistent prescription demand, this therapy helps strengthen specialty medicine portfolios and supports sustained growth by addressing critical platelet management needs in clinical practice.

Common side effects may include headache, nausea, diarrhea, fatigue, and upper respiratory tract infections. Rarely, elevated liver enzymes, thromboembolic events, or cataract formation may occur.

Eltrohype 50 Tablet is indicated for the treatment of chronic immune thrombocytopenia (ITP) in patients who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. It is also used in thrombocytopenia associated with chronic hepatitis C and severe aplastic anemia as prescribed by a physician.

Use this medicine strictly under medical supervision. Regular monitoring of platelet count and liver function tests is essential during treatment. Do not exceed the recommended dosage. Inform the doctor about any history of liver disease or clotting disorders.

Store below 25°C in a cool, dry place. Protect from light and moisture. Keep out of reach of children.

Get in Touch

Regulatory Compliance & Professional Verification

This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.

  • No Consumer Sale: We do not entertain retail inquiries or direct sales to patients.
  • Information Accuracy: While we strive for accuracy, product availability, packaging, and regulatory status may change based on CDSCO guidelines and state-specific drug laws.
  • Medical Advice: Patients are strictly advised not to self-medicate or use this information for treatment. Always consult a qualified medical practitioner.
  • Licensing: All business associations are subject to the submission of valid GST and Drug License (DL) documentation.

Strategic Advisory

Ms. Shiwani Dhiman

VP-Strategic Outreach & Engagement

Ms. Shiwani specializes in market outreach and strategic partnership orchestration for entrepreneurs building scalable PCD Pharma Franchise models.

View Professional Profile

Start Your Journey

Partner With Cafoli

Ready to Dominate your territory with a Monopoly-Based PCD Franchise? Join our rapidly growing network of successful franchise partners and turn your ambitions into reality. Limited Territories Available — Don’t Miss Out!

Quick Navigation